AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. reported growth YoY (%) (%)
Form 8-K Key Product Revenues Schedule
Latest, FY2025
6.7%
Period ended Dec 31, 2025
Change on a year earlier
+16.4 pts
-9.7% in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.7% | +16.4 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | -9.7% | +3.0 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | -12.7% | -12.9 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 0.2% | +4.2 pts | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | -4.0% | +42.7 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | -46.7% | -37.9 pts | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| FY2019 | Dec 31, 2019 | -8.8% | – | Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗ |
Cite this data
StockData. (2026). AbbVie Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. reported growth YoY (%) (%), annual FY2019–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/mavyret_us_rep_yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.